Tariquidar clinical trials
Also written XR9576.
How each study uses tariquidar is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 4
National Cancer Institute (NCI) (4) · QLT Inc. (2)
Often tested with
Tested in the same studies.
Vinorelbine (2) · Docetaxel (1) · Paclitaxel (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses tariquidar is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00011414Written as Tariquidar
- Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerCompletedPhase 2National Cancer Institute (NCI)NCT00069160Written as tariquidar
- Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical CancerCompletedPhase 2National Cancer Institute (NCI)NCT00071058Written as XR9576 (Tariquidar)
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 3QLT Inc.NCT00042302Written as tariquidar + paclitaxel/carboplatin
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 3QLT Inc.NCT00042315Written as tariquidar + vinorelbine
- Vinorelbine and XR9576 to Treat CancerCompletedPhase 1National Cancer Institute (NCI)NCT00001944Written as XR9576
Given beside what is tested · 1 — tariquidar is usual care or a partner of the new treatment
Codes
What other systems call tariquidar · ClinicalTrials.gg INT004197
- MeSH (NLM) C402343tariquidarOne source NLM
- UNII (FDA) J58862DTVDTARIQUIDARConfirmed FDA, NLM, Wikidata
- Wikidata Q7686198tariquidarConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2246TariquidarOne source FDA
- DrugBank DB06240One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C402343 | tariquidar | One source NLM |
| UNII (FDA) | J58862DTVD | TARIQUIDAR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7686198 | tariquidar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2246 | Tariquidar | One source FDA |
| DrugBank | DB06240 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.